BioNTech SE filed a Form 6-K with the SEC on November 10, 2026, announcing that it has entered into an agreement to acquire a U.S. FDA Priority Review Voucher from Scholar Rock, Inc. for a total cash consideration of $205 million.
Taiwan Semiconductor Manufacturing Company Limited filed a Form 6-K with the SEC on November 10, 2026, reporting its consolidated net revenue figures for October 2026 and the January through October 2026 year-to-date period.
SUNation Energy, Inc. filed a Form 8-K on November 10, 2026, disclosing under Item 7.01 (Regulation FD) that its merger target, Suniva, Inc., announced the start of construction on a new 4.5 GW solar cell manufacturing facility in Laurens County, South Carolina.
Bryan McLaren, Chairman, CEO and CFO of Zoned Properties, Inc. (OTC:ZDPY), filed a Form 4 on November 10, 2026, disclosing a restricted stock grant of 250,000 shares of common stock on October 30, 2026, made pursuant to a Severance Agreement dated that same day.
SUNation Energy, Inc. filed a current report on Form 8-K on November 10, 2026, disclosing that merger target Suniva, Inc. announced construction is underway on a new solar cell manufacturing facility in Laurens County, South Carolina.
Berekk Alan Blackwell, Former President and COO of Zoned Properties, Inc., filed a Form 4 on November 10, 2026, disclosing the acquisition of 150,000 shares of common stock on October 30, 2026, at a price of $0 per share under a severance agreement.
Chicago Atlantic Real Estate Finance, Inc. filed an 8-K with the SEC on November 10, 2026, announcing its financial results for the third quarter ended September 30, 2026, and disclosing details related to its proposed merger with Chicago Atlantic BDC, Inc.
Chicago Atlantic Real Estate Finance, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 10, 2026, reporting third-quarter net income of $6,434,023 and total assets of $468,192,211.
Protalix BioTherapeutics, Inc. filed a Form 10-Q with the SEC on November 10, 2026, reporting unaudited condensed consolidated financial results for the quarterly period ended September 30, 2026.
Boundless Bio, Inc. filed its quarterly report on Form 10-Q with the SEC on November 10, 2026, covering the three-month period ended September 30, 2026, and disclosing a pending merger with Serapha Bio, Inc. as a central development.